{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060238","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.639383+00:00","generated_at":"2026-06-08T16:57:52.318094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027","bullets":["Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.","Cash and short-term investments $349.7M, up from $327.0M at year-end 2022, expected to fund operations through 2027.","Enrollment ongoing for JANX007 (PSMA-TRACTr) in prostate cancer and JANX008 (EGFR-TRACTr) in solid tumors; update expected in 2024.","IND-enabling studies completed for JANX009 (PD-L1xCD28 TRACIr); TROP2-TRACTr candidate identified."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060238","json":"https://secwatch.observer/filing/0000950170-23-060238.json","markdown":"https://secwatch.observer/filing/0000950170-23-060238.md","text":"https://secwatch.observer/filing/0000950170-23-060238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/0000950170-23-060238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/janx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:57:52.318094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"190cb6e42785cefdee8c0ae6afc98686939ba286","claim":"Janux Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $11.6 million.","evidence_excerpt":"Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/0000950170-23-060238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $11.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}